Table 4.

Comparison of gene expression changes in rats treated with vorozole and in a large human anastrozole trial

Gene accessionGene symbolRat PRat fold changeAI PAl fold change
NM-001067TOP2A0.000999−2.55<1E−07−2.25
NM-016448DTL0.036154−1.36<1E−07−1.93
NM-003981PRC10.001101−1.75<1E−07−1.87
NM-018136ASPM0.020384−1.39<1E−07−1.75
NM-016343CENPF0.000936−2.17<1E−07−1.67
NM-198434STK6/AURKA0.030631−1.39<1E−07−1.61
NM-005733KIF20A0.016284−1.35<1E−07−1.58
NM-012112TPX20.000167−2.27<1E−07−1.57
NM-001071TYMS0.035359−1.42<1E−07−1.55
NM-014736KIAA01010.128767−1.51<1E−07−1.49
NM-018492PBK0.001512−2.43<1E−07−1.48
NM-031966CCNB10.007892−1.72<1E−07−1.47
NM-018131CEP550.042329−1.35<1E−07−1.44
NM-005192CDKN30.000163−1.93<1E−07−1.37
NM-012485HMMR0.00776−1.89<1E−07−1.36
NM-014791MELK0.000783−1.50600.E−07−1.36
NM-001211BUB1B0.002126−1.63<1E−07−1.36
NM-001237CCNA20.002509−1.805.00E−07−1.35
NM-003318TTK0.002163−1.84<1E−07−1.34
NM-004336BUB10.00652−2.11<1E−07−1.34
NM-033379CDC20.003485−1.93<1E−07−1.30
NM-005252FOS0.0304521.240.0244935−1.26
NM-057749CCNE20.026187−1.385.75E−05−1.20
NM-012291ESPL10.010255−1.16100E−06−1.17
NM-002417MK1670.005442−2.062.49E−05−1.11
NM-024680E2F80.001101−1.366.74E−05−1.10
NM-018098ECT20.003074−1.860.0344481−1.04
NM-133504DCN0.024762−1.560.00009−1.25
NM-012732LIPA0.0254491.654.00E−02−1.11
NM-001106281PRCP0.0405761.584.00E−03−1.11

NOTE: The results obtained with vorozole in the rat were compared with results in a human trial of anastrozole, which included 81 paired samples of human ER+ breast cancer (baseline tissue before anastrozole and a biopsy at 2–4 weeks after the initiation of anastrozole; ref. 22).

Abbreviation: AI, aromatase inhibitor.